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Urinary incontinence has become a societal problem that affects millions of people 
worldwide. Although numerous therapeutic modalities are available, none has been 
shown to be entirely satisfactory. Consequently, cell-based approaches using re-
generative medicine technology have emerged as a potential solution that would pro-
vide a means of correcting anatomical deficiencies and restoring normal function. As 
such, numerous cell-based investigations have been performed to develop systems that 
are focused on addressing clinical needs. While most of these attempts remain in the 
experimental stages, several clinical trials are being designed or are in progress. This 
article provides an overview of the cell-based approaches that utilize various cell sour-
ces to develop effective treatment modalities for urinary incontinence.
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Urinary incontinence, which is characterized as any in-
voluntary leakage of urine, is a social and distressing prob-
lem that affects approximately 25 percent of women and 
9 percent of men [1,2]. Although urinary incontinence is 
classified by a variety of types, the underlying pathology 
can be grouped into two major categories: urethral hyper-
mobility and intrinsic sphincter deficiency [3]. However, 
most cases of urinary incontinence exist between the ex-
tremes of these two categories, and most patients have ele-
ments of both disorders [4]. Although conservative man-
agement, such as dietary and lifestyle changes, pelvic floor 
muscle training, and pharmacologic agents, has been 
somewhat helpful in alleviating symptoms in mild con-
ditions, these measures do not correct the underlying path-
ology [5-9]. In contrast, surgical and interventional proce-
dures seek to increase the coaptation pressure of the ure-
thral sphincter by means of sling procedures, artificial 
sphincter placement, and injectable bulking agents [10]. 
Sling procedures are considered the gold standard in cor-
recting the underlying anatomical deformities, with suc-
cess rates ranging from 80% to 94% [11-13]. However, com-
plications associated with these procedures and long-term 
consequences of urethral and vaginal erosions of the sling 
materials remain as unsolved challenges. Injectable bulk-
ing agents, such as polytetrafluoroethylene, bovine colla-
gen, silicone particles, and carbon beads, have also been ap-
plied clinically as a treatment modality for incontinence. 
These agents are designed to augment urethral and blad-
der neck tissues by increasing resistance to urine flow, but 
they have minimal effects on urethral mobility. As such, 
approximately 25% of patients with incontinence show cor-
rection of urinary incontinence, whereas 50% demonstrate 
improvement and the remaining 25% experience treat-
ment failure [14,15]. More importantly, untoward effects 
associated with the bulking agents, including long-term bi-
ocompatibility, recurrence, inflammatory responses, mi-
gration, and erosion, remain a problem [11,16].
Due to the limitations of the current treatment modal-
ities for urinary incontinence, investigators have sought 
alternative approaches to treating urinary incontinence. 
Regenerative medicine has emerged as an innovative sci-
entific field that focuses on the development of new ap-
proaches to repairing cells, tissues, and organs for clinical 
applications. Recent advances in cell-based technology us-
ing regenerative medicine techniques suggest that this ap-
proach holds enormous potential to improve human con-
ditions by encompassing alteration of the current bio-
logical state of a targeted tissue, augmentation of depleted 
function, or absolute functional tissue replacement [17- 
19]. Consequently, efforts in cell-based technology have fo-
cused on developing systems that would restore and main-
tain normal tissue function. To that end, numerous cell- 
based investigations have been performed to address uri-
nary incontinence. This article aims to provide an overview Korean J Urol 2010;51:1-7
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of the cell-based investigations that utilize a wide range of 
cell sources to overcome the limitations of current treat-
ment modalities for urinary incontinence.
FUNDAMENTALS OF CELL-BASED THERAPY 
FOR URINARY INCONTINENCE
The basic components required to achieve functional tis-
sues and organs are cells, scaffolds, and the in vivo environ-
ment [17,18]. Regenerative medicine strategies that have 
been demonstrated to be successful involve the use of bio-
compatible matrices either with or without cells. The ma-
trices are used either as supporting scaffolds to promote 
and facilitate tissue regeneration over smaller gaps or as 
cell delivery vehicles for larger defects. When cells are used, 
donor tissue is dissociated into individual cells, which are 
expanded in culture, combined with a support matrix, and 
introduced into the body to form mature and functional 
tissues. The cells can be delivered into the target region sur-
gically or through a needle injection, depending on the type 
of tissue applications. Cells for tissue reconstitution can be 
derived from the native organ to be replaced, thus avoiding 
rejection. In instances where normal tissues are not avail-
able, different cell sources may be explored. Stem and pro-
genitor cells offer numerous opportunities in regenerative 
medicine. Cells derived from various stages of develop-
ment can be either implanted directly in the target tissues 
or guided into specific cell lineages in vitro followed by im-
plantation in vivo.
Cells are an essential component required to augment 
tissue function for urinary incontinence. Cells derived 
from various sources have been used for urinary incon-
tinence, including chondrocytes, smooth muscle cells, mus-
cle precursor cells (MPCs), adipose-derived stem cells, and 
bone marrow stromal cells [20]. The use of these cells is 
aimed at achieving coaptation of the bladder neck region 
by augmenting tissue mass or restoring sphincter function. 
To use cells for application in urinary incontinence, a cell 
expansion system that permits recovery of large quantities 
of target cells must be developed. This has been one of the 
challenges that is being continuously investigated. Even 
when some organs, such as the liver, have a high re-
generative capacity in vivo, in vitro expansion of cells de-
rived from these organs has proved to be difficult. However, 
the discovery of privileged sites for committed precursor 
cells in specific organs and extensive study of the conditions 
that promote precursor cell maintenance and differ-
entiation within these sites have begun to overcome some 
of the limitations associated with cell expansion in vitro. 
Urothelial cells, for instance, have been grown in culture 
in the past, but with only limited success. However, several 
novel culture protocols have been developed over the past 
two decades that allow for the maintenance of precursor 
cells in an undifferentiated state. Because these cells can 
remain in the growth phase, the ability to expand ur-
othelial cultures is vastly improved [21-24]. These studies 
indicate that it may be possible to collect autologous cells 
from patient’s tissues, expand them in culture, and return 
them to the donor in sufficient quantities for reconstructive 
purposes [23,25-30].
Biomaterials for various cell-based therapies are usu-
ally designed to replicate the biological and mechanical 
functions of native tissue structures and their ex-
tracellular matrix (ECM). They provide three-dimensional 
architecture for cells to reconstitute into new tissues and 
allow for the delivery of cells and bioactive factors (e.g., pep-
tides, growth factors) to desired sites in the body to enhance 
functionality [31]. Because most mammalian cell types are 
anchorage-dependent, biomaterials serve as a cell-adhe-
sion substrate that can deliver cells to specific regions of 
the body with a high loading efficiency. An ideal bio-
material for cell therapy should be biodegradable and ab-
sorbable without eliciting inflammatory responses that in-
terfere with cellular function and tissue formation. Incom-
patible materials are destined for an inflammatory or for-
eign-body response that eventually leads to rejection or 
necrosis. Because biomaterials for cell therapy provide 
temporary mechanical support while the cells undergo spa-
tial tissue organization, a suitable biomaterial should 
maintain adequate mechanical integrity to support tissue 
formation during early stages of development. To develop 
a suitable biomaterial for the cell-based treatment of uri-
nary incontinence, various factors need to be considered, 
including biocompatibility, biodegradation, and struc-
tural and mechanical properties. These materials should 
be able to 1) facilitate the delivery of cells to target sites in 
the urethra and bladder neck region, 2) maintain the 
three-dimensional architecture that permits formation of 
new tissues, and 3) guide the development of new tissues 
with appropriate function [31]. As such, numerous bio-
materials, both synthetic and naturally derived, have been 
developed and used as substrates for urinary incontinence, 
including collagen and alginate [32-37].
To achieve functional tissue in vivo, implanted cells 
must maintain viability by obtaining an adequate supply 
of nutrients and oxygen. One of the continued challenges 
in engineering clinically relevant tissues is the establish-
ment of vascularization for implanted tissues and organs. 
This is especially true for large tissue masses consisting of 
cell-based implants that require a sufficient blood supply 
to maintain viability. It is well known that cellular im-
plants that are more than a few hundred microns away 
from a blood vessel will not survive because of diffusion 
limitations. Consequently, tissue implants that are unable 
to establish vascularization in time result in cell death and 
tissue necrosis [38]. This has been a critical limiting factor 
for developing functional tissues for human applications 
[39]. An approach to maintaining tissue viability in vivo is 
to place the engineered tissue adjacent to a heavily vascu-
larized tissue such as the omentum to achieve adequate 
vascularization [40]. However, this approach may not al-
ways be feasible because the target implantation site may 
not be in close proximity. To overcome this limitation, sev-
eral strategies have been used to facilitate the delivery of Korean J Urol 2010;51:1-7
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oxygen and improve the survival of implanted cells. 
Angiogenic growth factors such as vascular endothelial 
growth factor (VEGF), which is a potent endothelial 
cell-specific mitogen, have been used to promote neo-vas-
cularization [41,42]. Although the effectiveness of an en-
hanced angiogenic response has been demonstrated in 
many tissue systems, the rate of angiogenesis cannot be ac-
celerated, thus limiting the size of implantable tissue 
masses [43]. Another approach to overcoming diffusion 
limitation is to configure biomaterials that facilitate vascu-
larization to implanted cells and tissues by modifying prop-
erties and porosity [44,45]. Recently, efforts have been 
placed in developing strategies to prolong cell survival un-
til host neovascularization is achieved by increasing oxy-
gen tension or incorporating oxygen-generating bioma-
terials [46,47].
CELL-BASED APPROACHES FOR URINARY 
INCONTINENCE
1. Injectable chondrocytes
One of the early investigations of cell therapy for urinary 
incontinence involved the use of autologous chondrocytes 
(cartilage cells). Chondrocytes were chosen as a tissue 
bulking agent because this cell type possesses an inherent 
ability to produce extracellular matrix and maintain struc-
tural integrity in vivo, thus providing ideal tissue bulking 
for the treatment of urinary incontinence [32]. In addition, 
chondrocytes can be easily isolated, grown, and expanded 
in culture conditions. Alginate, a liquid solution of gluronic 
and mannuronic acid, serves as a substrate for the delivery 
of chondrocytes through a needle. In a preclinical study 
demonstrating the feasibility of using chondrocytes as a 
bulking agent, autologous chondrocytes from porcine ear 
cartilage were grown and expanded in culture. The chon-
drocytes, suspended in alginate, were then injected endo-
scopically to correct anatomical deformities of the ves-
icoureteral junction. This study showed that chondrocytes 
combined with alginate in vitro can be easily injected cys-
toscopically, and that the elastic cartilage tissue formed 
within the injection region can correct vesicoureteral re-
flux without any evidence of obstruction [48].
Based on the results of multiple experimental studies, 
two multicenter clinical trials were conducted using the en-
gineered chondrocyte technology. In one study, patients 
with vesicoureteral reflux were treated at 10 centers across 
the United States by following the same strategy that in-
volved the use of autologous chondrocytes combined with 
alginate. The patients had a success rate similar to that 
with other injectable substances in terms of cure [49]. In 
the second study, patients with urinary incontinence were 
treated endoscopically with injected chondrocytes at three 
different medical centers in the United States. Thirty-two 
patients received a single outpatient injection just distal 
to the bladder neck. The investigators concluded that this 
treatment was safe, effective, and durable, with 50% of pa-
tients remaining completely dry 12 months after a single 
injection. Twenty-six of 32 patients reported at least some 
improvements at 3 months after the injection that con-
tinued until at least the 12-month follow-up visit [32].
2. Injectable muscle cells
The potential use of injectable cultured myoblasts for the 
treatment of stress urinary incontinence has been inves-
tigated [50,51]. Labeled myoblasts were directly injected 
into the proximal urethra and lateral bladder walls of athy-
mic mice with a micro-syringe in an open surgical pro-
cedure. Tissue harvested up to 35 days after injection con-
tained the labeled myoblasts, as well as evidence of differ-
entiation into regenerative myofibers. This study showed 
that a significant portion of the injected myoblast pop-
ulation persisted in vivo. Similar techniques of sphinc-
ter-derived muscle cells have been used for the treatment 
of urinary incontinence in a pig model [52]. The fact that 
myoblasts can be labeled and survive after injection and be-
gin the process of myogenic differentiation supports the 
feasibility of using cultured cells of muscular origin as an 
injectable bioimplant.
The use of injectable MPCs has also been investigated 
for use in the treatment of urinary incontinence due to irre-
versible urethral sphincter injury or developmental de-
fects. MPCs are the quiescent satellite cells found in each 
myofiber that can proliferate to form myoblasts and even-
tually myotubes and new muscle tissue. The standard 
MPC grafting technique consists of an injection of cells that 
were originally harvested from a muscle biopsy by enzymatic 
digestion and then cultured under specific conditions to elim-
inate nonmyogenic cells. However, there is now increasing 
evidence that these successive steps of MPC preparation al-
ter the myogenic potential of these cells in vivo [53,54].
MPCs have been shown to play an active role in the re-
generation of injured striated urethral sphincter [55]. In 
a subsequent study, autologous MPCs were injected into 
a rat model of urethral sphincter injury, and replacement 
of mature myotubes as well as restoration of functional mo-
tor units were noted in the regenerating sphincter muscle 
tissue [56]. This was the first demonstration of the replace-
ment of both sphincter muscle tissue and its innervation 
by the injection of MPCs, which suggests that MPCs may 
be a minimally invasive solution for urinary incontinence 
in patients with irreversible urinary sphincter muscle 
insufficiency. Another study investigated a method of in-
traurethral MPC transplantation consisting of implanting 
freshly isolated myofibers with their satellite cells. The in-
vestigators hypothesized that myofiber death after im-
plantation would induce activation of satellite cells in vivo, 
thus avoiding the necessity for MPC extraction and in vitro 
expansion [57]. Histological studies showed that the myo-
genic process, consisting of myofiber degeneration and sat-
ellite cell activation, was observed at 7 days after trans-
plantation, followed by myotube formation replacing pa-
rental myofibers at 30 days. In the subsequent experi-
ments, implantation of myofiber strips to endoscopic 
sphincter injured urethra generated a pressure peak that Korean J Urol 2010;51:1-7
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decreased after endoscopic injury and reappeared 60 mi-
nutes later, indicating that this action was tonic and under 
neural control. Histologically, the myotubes were oriented 
in the same direction as the parental myofibers, suggesting 
that satellite cell fusion was guided by the tubes of ex-
tracellular matrix surrounding each myofiber. There was 
evidence that new nerve fibers developed in the vicinity of 
the implanted myotubules, and neural tissue was present 
in greater density than in surrounding tissue. These find-
ings suggest the presence of concomitant neuronal devel-
opment and innervation of the transplanted myofibers. In 
contrast, the experimental results of another animal study 
indicated that the improvement of muscle regeneration was 
not better than that with muscle-derived stem cells [58]. The 
reasons for this discrepancy remain to be explored.
Cultured myoblasts are one of the most studied cell 
types for the treatment of incontinence [59,60]. The fact 
that MPCs survive after injection and initiate the process 
of myogenic differentiation further supports the feasibility 
of using cultured cells of muscular origin as an injectable 
bioimplant [56]. Although many studies have been per-
formed in laboratory settings using protocols developed for 
animal cells to demonstrate the principle and feasibility of 
using cultured cells of muscular origin, culture systems 
compatible with clinical application are needed [61,62]. 
One problem in these established protocols is the use of ex-
tracellular matrix proteins derived from cancer cells 
(Matrigel
Ⓡ, BD Biosciences, San Jose, USA), which contain 
a high concentration of various growth factors and are com-
monly used to promote the proliferation and differentia-
tion of muscle precursors. In order to achieve rapid clinical 
translation of MPC therapy, culture conditions were opti-
mized for human application. A human MPC culture sys-
tem that uses FDA-approved substrates with defined me-
dia for expansion and differentiation was developed [62]. 
An interesting clinical trial that used striated mus-
cle-derived myoblast transplantation was reported by 
Strasser et al [63]. Using transurethral ultrasound-guided 
injections of autologous myoblasts and fibroblasts, 42 pa-
tients (29 women, 13 men) with urinary stress incontinence 
were treated. In 35 patients, urinary incontinence was 
completely cured. In seven patients who had undergone 
multiple surgical procedures and radiotherapy, urinary in-
continence improved but was not eliminated. No side ef-
fects or complications were reported postoperatively. In 
this study, the authors concluded that urinary incon-
tinence can be treated effectively with autologous stem 
cells. It is noteworthy that this represents the first attempt 
to use an autologous stem cell strategy in clinical urology. 
The same investigators conducted a randomized controlled 
trial comparing ultrasound-guided transurethral rhab-
dosphincter injection of autologous myoblasts and fibro-
blasts vs. transurethral collagen injection for incontinence 
in 63 eligible women [64]. At the follow-up examination at 
12 months, 38 of the 42 women injected with autologous 
cells were completely continent, compared with 2 of the 21 
patients given conventional treatment with collagen. 
However, this report was later retracted by the Lancet be-
cause of several controversial issues [65]. Despite the re-
traction of the report on this clinical trial, several other 
FDA-approved cell therapy clinical trials targeting incon-
tinence are on the horizon (http://www.clinicaltrials.gov).
3. Stem cells
One of the objectives of regenerative medicine therapy for 
incontinence is reconstruction of the sphincter muscle 
itself. Stem cells have been proposed as a promising cell 
source to replace, repair, or enhance the biological func-
tions of damaged sphincter [66]. Stem cells are defined by 
their ability to self-renew and differentiate into a variety 
of cell types. They are further classified by the breadth of 
cell lineages into which they may potentially differentiate 
[67]. Research that explores the possible applications of 
stem cells in the field of urology has been increasing. The 
current strategy for the cell-based approach to build func-
tional tissues uses autologous cells from the diseased 
organs. However, in instances where normal cells cannot 
be obtained because of extensive end-stage disease, stem 
cells are envisioned as an ideal source of cells because they 
can differentiate into desired cell types if guided appropri-
ately [68].
The pluripotency of human embryonic stem cells is 
highlighted by their ability to form embryoid bodies in vi-
tro, which are cell aggregations that contain all three germ 
layers. The use of embryonic stem cells as a primary non-
immunogenic tissue source for seeding of decellularized 
scaffolds has been heavily investigated [69]. However, clin-
ical applications using embryonic stem cells are faced with 
several challenges, including the propensity of these cells 
to form teratomas in vivo and ethical concerns about the 
destruction of human embryos [70]. Recently, fetal stem 
cells derived from amniotic fluid and placenta have been 
described and represent a novel source of stem cells [71,72]. 
These cells express markers consistent with human em-
bryonic stem cells, such as OCT4 and SSEA-4, but they do 
not form teratomas. The cells are multipotent and can dif-
ferentiate into cells from all three germ layers. In addition, 
the cells have high replicative potential and can be stored 
for future self-use, without the risks for rejection and with-
out ethical concerns [73]. Although these cells do differ-
entiate into the myogenic lineage, further studies are nec-
essary to determine their utility in urinary incontinence 
applications.
Multipotent stem cells have become an attractive op-
tion for stem cell therapies in many organ systems, includ-
ing the urologic system. The use of these cells avoids the 
controversy surrounding human embryonic stem cells, and 
unlike embryonic cells, they do not trans-differentiate into 
a malignant phenotype. Thus, there is a diminished risk 
for teratoma formation when implanted in vivo and they 
can be extracted from many different tissues, including 
bone marrow, striated muscle, fat, skin, testicle, and syno-
vial membrane [74]. Adult-derived stem cells, such as adi-
pose-derived stem cells and bone marrow stromal cells or Korean J Urol 2010;51:1-7
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mesenchymal stem cells (MSCs), are gaining popularity 
because they have a more extensive differentiation poten-
tial than previously reported [75-77]. One limitation that 
hampers rapid clinical translation is the expandability of 
the cells. Strategies to overcome this limitation are being 
developed, such as adding growth factors to the injected 
cells to stimulate proliferation or culturing cells on bio-
degradable matrices composed of natural extracellular 
matrix proteins or synthetic polymers [78-80].
The use of adipose-derived stem cells has been explored 
for the treatment of urinary incontinence [81]. Processed 
lipoaspirate (PLA) cells are abundant in the adipose tissue, 
and they are amenable to harvesting under local anes-
thesia. These cells are phenotypically similar to mesen-
chymal stem cells and have been shown to differentiate into 
adipogenic, chondrogenic, osteogenic, neurogenic, and 
myogenic lineages [82]. In one study, lipoaspirates from fe-
male patients undergoing liposuction were processed to 
yield a pluripotent population of PLA cells that were in-
jected into the bladder and urethra. Eight weeks after in-
jection, PLA cells demonstrated the expression of alpha- 
smooth muscle actin, an early marker of smooth muscle 
differentiation. This study suggests that PLA cells are an 
easily accessible source of pluripotent cells, making them 
ideal for tissue regeneration. Human PLA cells injected in-
to the urinary tract show morphological and phenotypic 
evidence of smooth muscle incorporation and differentia-
tion over time. In another study, the effects of adipose- de-
rived stem cells isolated from the peri-ovary fat were im-
planted in a rat model of incontinence [83]. This study 
showed that the treated animals showed a normal voiding 
pattern and possessed higher elastin and smooth muscle 
content than did untreated incontinent animals.
Bone marrow derived MSCs have been used as a cell 
source for the treatment of urinary incontinence [84]. 
MSCs were exposed to 5-azacytidine to induce myogenic 
differentiation and were culture expanded. Subsequently, 
these cells were implanted into the bladder neck region of 
athymic rats. The results of this study suggested that the 
use of MSCs for the treatment of urinary incontinence may 
be a feasible option [84].
CONCLUSIONS
Rapid advances in cell-based technologies have provided 
innovative therapeutic opportunities for numerous hu-
man conditions. This article presents cell-based appro-
aches that are designed to address the challenges involved 
with the current treatment modalities for urinary incon-
tinence. These include the use of a wide spectrum of cell 
sources ranging from nonurologic autologous cells to stem 
cells at various stages of development. Although the cur-
rent status of research in this area remains mostly in the 
laboratory, several technologies are currently being devel-
oped and validated clinically. These innovative develop-
ments have generated enormous hope and anticipation 
that the new modalities will provide effective treatments 
and improve the quality of life of millions of patients in the 
near future.
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